A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Theriau, Christopher F.
Feng, Jamie
Eng, Lawson
Shepherd, Frances A.
DeCarolis, Mary
Glenns, Vivian
Kulkarni, Swati
VanderMeer, Rachel
Zurawska-Fortin, Urszula
Hao, Desiree
Le, Lisa
Wozniczka, Isabel
Al-Kindy, Aida
Xie, Danny
Zhang, Tong
Subramanian, Vasanth
Stockley, Tracy
Bradbury, Penelope A.
Liu, Geoffrey
Leighl, Natasha B.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT206
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
    Fung, A. S.
    Graham, D. M.
    Chen, E. X.
    Stockley, T. L.
    Zhang, T.
    Le, L. W.
    Albaba, H.
    Pisters, K. M.
    Bradbury, P. A.
    Trinkaus, M.
    Chan, M.
    Arif, S.
    Zurawska, U.
    Rothenstein, J.
    Zawisza, D.
    Effendi, S.
    Gill, S.
    Sawczak, M.
    Law, J. H.
    Leighl, N. B.
    LUNG CANCER, 2021, 157 : 21 - 29
  • [2] Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
    Haslett, K.
    Koh, P.
    Hudson, A.
    Ryder, W. D.
    Falk, S.
    Mullan, D.
    Taylor, B.
    Califano, R.
    Blackhall, F.
    Faivre-Finn, C.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 28 : 24 - 31
  • [3] Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
    Phu Tran
    Gooding, William E.
    Villaruz, Liza Cosca
    Burns, Timothy Francis
    Socinski, Mark A.
    Tarhini, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Nagasaka, M.
    Goto, K.
    Gomez, J.
    Hida, T.
    Shu, C.
    Lee, C. K.
    Park, K.
    Cho, B. C.
    Lee, J.
    Ou, S.
    Bestvina, C.
    Natale, R.
    Haddish-Berhane, N.
    Bhattacharya, A.
    Verheijen, R.
    Agrawal, T.
    Knoblauch, R.
    Govindan, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1116
  • [6] A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC).
    Hoffman, PC
    Mauer, AM
    Haraf, DC
    Lester, EP
    Szeto, LL
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [7] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [8] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer
    Okuda, Kentaro
    Hirose, Takashi
    Ishida, Hiroo
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Ando, Kohichi
    Shirai, Takao
    Ohnishi, Tsukasa
    Horichi, Naoya
    Ohmori, Tohru
    Adachi, Mitsuru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 829 - 835
12345